Novo Nordisk to slash Wegovy, Ozempic list prices
Board licensed rheumatologist Dr. Mahsa Tehrani discusses Novo Nordisk’s determination to dramatically reduce the U.S. record costs for its in style diabetes and weight-loss medication Ozempic and Wegovy on ‘America Experiences.’
NEWNow you can take heed to Fox Information articles!
Tens of millions of Medicare beneficiaries struggling with obesity might quickly see the price of weight-loss medication plummet, as a brand new federal pilot program launching July 1 expands entry to GLP-1 medicines like Wegovy and Zepbound for eligible seniors.
By way of a brand new trial known as Medicare GLP-1 Bridge, the federal authorities is now providing a number of the brand-name medicines to sure Medicare and Medicare Benefit beneficiaries for $50 a month, The Related Press reported.
The covered medications embrace drugmaker Eli Lilly’s Foundayo tablets and Zepbound KwikPens and Novo Nordisk’s Wegovy injections and tablets, all of which have been FDA-approved for weight reduction, in keeping with the report.
OZEMPIC USERS MAY BE MAKING A MAJOR WEIGHT-LOSS MISTAKE, NEW STUDY SUGGESTS
The short-term program is ready to run till the tip of 2027.
That is the primary time GLP-1s (glucagon-like peptide-1 receptor agonists) shall be lined by insurance coverage when used solely for weight loss.
A brand new federal pilot program launching July 1 expands entry to GLP-1 medicines like Wegovy and Zepbound for eligible seniors. (iStock)
Previous to this new Medicare pilot, seniors who wished to entry GLP-1s for weight problems alone paid about $1,350-$1,650 per thirty days for Novo Nordisk’s Wegovy (semaglutide) and about $1,086 month-to-month for Lilly’s Zepbound (tirzepatide). Nonetheless, each producers supplied some cash-pay choices that considerably decreased these costs for eligible sufferers.
There are some parameters surrounding the protection — older adults should have had a physique mass index (BMI) of 35 or increased once they began GLP-1 remedy, or a BMI of 27 or increased alongside one other well being situation, resembling a previous heart attack or stroke or prediabetes.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Those that have already got insurance coverage protection for different illnesses, such as diabetes and sleep apnea, are usually not eligible for this system.
By way of a brand new trial known as Medicare GLP-1 Bridge, the federal authorities is now providing a number of the brand-name medicines to sure Medicare and Medicare Benefit beneficiaries for $50 a month. (iStock)
There are greater than 70 million People at present enrolled in Medicare, 10 million of whom are obese or overweight, in keeping with Juliette Cubanski, vp and director of this system on Medicare coverage on the healthcare analysis nonprofit KFF.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“For a lot of older People residing with weight problems, it is a second they and their households have been ready for,” Jamey Millar, Novo Nordisk’s government vp of U.S. operations, mentioned in a press launch.
“The Medicare GLP-1 Bridge program affords a brand new, inexpensive path to an FDA-approved therapy that was beforehand not lined.”
CLICK HERE FOR MORE HEALTH STORIES
Dr. Mehmet Oz, administrator of the Facilities for Medicare & Medicaid Companies, mentioned he hopes this system may also help his company accumulate information to probably work towards longer-term protection, whereas offering fast reduction to cash-strapped older People, AP reported.
“The sheer price of these medications is a big barrier to entry,” he mentioned in a name with reporters. “That ends immediately.”
Previous to this new Medicare pilot, seniors who wished to entry GLP-1s for weight problems alone paid about $1,350-$1,650 per thirty days for Novo Nordisk’s Wegovy (semaglutide) and about $1,086 month-to-month for Lilly’s Zepbound (tirzepatide). (iStock)
Oz instructed reporters that CMS plans to “rigorously monitor participation and outcomes” to see whether or not an extension of the Bridge program or one other resolution is one of the best ways to maneuver ahead. He instructed AP a federal law completely permitting the protection is “not important proper now” however one thing “for Congress to debate amongst themselves.”
“We will’t determine what’s going to occur long run with Bridge till we see a few of the information,” he mentioned, including that there are ongoing talks with drug corporations to decrease prices.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
One potential concern is that older patients are inclined to have extra antagonistic results to remedy normally , in keeping with Dr. Micah Eimer, a medical assistant professor of cardiology on the Northwestern College Feinberg College of Medication.
“Particularly, in our analysis, older sufferers on blood strain medicines have been extra more likely to expertise hypotensive uncomfortable side effects, resembling fainting and dizziness, after beginning a GLP-1,” he mentioned in an announcement.
The Related Press contributed to this report.
